Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940287 | 1.00 | SLC6A9 (0.47) | SLC6A9NOTUMAOC3KCNH2GPR55 | |
| SCHEMBL2937599 | 0.89 | SLC6A9 (0.50) | SLC6A9NOTUMAOC3KCNH2GPR55 | |
| SCHEMBL2937602 | 0.89 | SLC6A9 (0.50) | SLC6A9NOTUMAOC3KCNH2GPR55 | |
| SCHEMBL2939303 | 0.85 | NOTUM (0.60) | SLC6A9NOTUM | |
| SCHEMBL2939305 | 0.85 | NOTUM (0.60) | SLC6A9NOTUM | |
| SCHEMBL13363551 | 0.81 | SLC6A9 (0.50) | SLC6A9NOTUMAOC3KCNH2GPR119 | |
| SCHEMBL2937750 | 0.81 | SLC6A9 (0.51) | SLC6A9KCNH2GPR55GPR119 | |
| SCHEMBL2937751 | 0.81 | SLC6A9 (0.51) | SLC6A9KCNH2GPR55GPR119 | |
| SCHEMBL2184348 | 0.78 | SLC6A9 (0.56) | SLC6A9AOC3KCNH2GPR55GPR119 | |
| SCHEMBL2939585 | 0.77 | SLC6A9 (0.48) | SLC6A9NOTUMKCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134704-B1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-09-22 | — | — | EP | disclosed |
| US-20100120807-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-05-13 | — | — | US | disclosed |
| EP-2134704-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109702-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120807-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | SLC6A9 2063/4885NOTUM 4356/4885AOC3 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.